Literature DB >> 25421663

Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options.

Xinbo Zhang1, Naimei Tang, Arun K Rishi, Harvey I Pass, Anil Wali.   

Abstract

Malignant Pleural Mesothelioma (MPM) is an aggressive malignancy of the pleura associated with asbestos exposure. Incidence of MPM is expected to increase over the course of next decade in both Europe and the developing countries. Although significant progress has been made in terms of etiology and pathogenesis of this disease, currently available therapeutic options have not significantly improved the survival outcome of patients on standard chemotherapeutic regimens. Integrity of the cellular DNA is often altered in many cancers. Understanding of the molecular mechanisms that regulate cellular DNA alterations to facilitate cancer initiation and development has potential to allow better design of cancer cell inhibitory strategies. In this context, there is a need to explore the gamut of "omics" strategies to provide a comprehensive epigenetics profile for MPM. This chapter discusses the functional genomics and epigenetic patterns observed by various investigators studying MPM patient populations on global fronts, and attempts to present a holistic approach in combating this insidious disease. Here we provide investigators in this field with novel insights and methodologies used in other types of cancers that might have profound impact in the early detection, prognosis and potential therapeutic strategies for MPM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25421663     DOI: 10.1007/978-1-4939-1804-1_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

Review 1.  Targeting the epigenome in malignant pleural mesothelioma.

Authors:  Kaitlin C McLoughlin; Andrew S Kaufman; David S Schrump
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 2.  Epigenetic polypharmacology: A new frontier for epi-drug discovery.

Authors:  Daniela Tomaselli; Alessia Lucidi; Dante Rotili; Antonello Mai
Journal:  Med Res Rev       Date:  2019-06-20       Impact factor: 12.944

3.  Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

Authors:  Douae Bensaid; Thibaut Blondy; Sophie Deshayes; Virginie Dehame; Philippe Bertrand; Marc Grégoire; Mohammed Errami; Christophe Blanquart
Journal:  Clin Epigenetics       Date:  2018-06-18       Impact factor: 6.551

Review 4.  Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.

Authors:  Luca Ferrari; Michele Carugno; Carolina Mensi; Angela Cecilia Pesatori
Journal:  Front Oncol       Date:  2020-04-03       Impact factor: 6.244

5.  New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment.

Authors:  Giovanni Cugliari; Alessandra Allione; Alessia Russo; Chiara Catalano; Elisabetta Casalone; Simonetta Guarrera; Federica Grosso; Daniela Ferrante; Marika Sculco; Marta La Vecchia; Chiara Pirazzini; Roberta Libener; Dario Mirabelli; Corrado Magnani; Irma Dianzani; Giuseppe Matullo
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

6.  An Integrated Analysis of the Genome-Wide Profiles of DNA Methylation and mRNA Expression Defining the Side Population of a Human Malignant Mesothelioma Cell Line.

Authors:  Myung-Chul Kim; Na-Yon Kim; Yu-Ri Seo; Yongbaek Kim
Journal:  J Cancer       Date:  2016-07-26       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.